Prenetics Global (PRE, Financial) experienced a notable stock drop of 5.89%, trading at $5.43 per share with a volume of 10,399 shares. The turnover rate was 0.09%, and the stock's amplitude reached 4.16%. Recent financial reports indicate that Prenetics Global reported revenue of $7.78 million and a net loss of $10.64 million, resulting in an earnings per share (EPS) of -$0.84. The gross profit stood at $2.23 million, with a price-to-earnings (P/E) ratio of -1.46. No institutional ratings are currently available for this stock.
Within the life sciences sector, there was an overall decline of 1.67%. Volitionrx Limited, Ispecimen Inc., and Annette Insurance saw significant gains. Active stocks included Ispecimen Inc., Applied DNA Sciences, Inc., and Inotiv, Inc. Prenetics Global Limited C/Wts 18/05/2027, Bioaffinity Technologies Inc C/Wts 07/09/2027, and Ispecimen Inc. showed notable amplitude.
Prenetics Global Ltd focuses on diagnostics and genetic testing, aiming to enhance global health access through preventive, diagnostic, and personalized care services across nine regions, including the UK, Hong Kong, India, South Africa, and Southeast Asia.
